Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:57:41 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



Q:SNGX - SOLIGENIX INC - http://www.dorbiopharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SNGX - Q0.50.398·0.42960.50.40-0.0045-1.1296.21123770.402  0.4297  0.39584.20  0.370517:58:31Apr 2515 min RT 2¢

Recent Trades - Last 10 of 377
Time ETExPriceChangeVolume
17:58:31Q0.40-0.004521
17:58:31Q0.3992-0.0053333
17:12:54Q0.4045 999
17:08:36Q0.4045 4,001
16:57:59Q0.420.01554
16:03:45Q0.4045 16
16:00:00Q0.4045 12
16:00:00Q0.4045 22
16:00:00Q0.4045 22
16:00:00Q0.4045 17

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-25 07:30U:SNGXNews ReleaseSoligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
2024-04-18 08:30U:SNGXNews ReleaseSoligenix Announces Pricing of $4.75 Million Public Offering
2024-04-15 07:30U:SNGXNews ReleaseFDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
2024-04-11 07:30U:SNGXNews ReleaseFDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
2024-04-03 07:30U:SNGXNews ReleaseSoligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte(TM) With the European Medicines Agency
2024-03-15 07:30U:SNGXNews ReleaseSoligenix Announces Recent Accomplishments and Year End 2023 Financial Results
2024-02-08 07:30U:SNGXNews ReleaseSoligenix Announces Formation of Beh ƒ §et's Disease Medical Advisory Board
2024-01-26 09:01U:SNGXNews ReleaseSoligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2024-01-25 07:30U:SNGXNews ReleaseSoligenix to Present at The Microcap Conference
2024-01-08 07:30U:SNGXNews ReleaseFDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Beh ƒ §et's Disease
2024-01-04 07:30U:SNGXNews ReleaseSoligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
2024-01-02 07:30U:SNGXNews ReleaseSoligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
2023-12-01 07:30U:SNGXNews Release"HyBryte ¢ „ ¢ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery
2023-11-30 07:30U:SNGXNews ReleaseSoligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Beh ƒ §et's Disease
2023-11-17 16:00U:SNGXNews ReleaseSoligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
2023-11-13 07:30U:SNGXNews ReleaseSoligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results
2023-10-20 16:00U:SNGXNews ReleaseSoligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
2023-10-20 09:02U:SNGXNews ReleaseASP Isotopes and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
2023-10-16 07:30U:SNGXNews ReleaseSoligenix to Present at The ThinkEquity Conference
2023-10-13 09:01U:SNGXNews ReleaseSPI Energy and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV